Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ORP003
MIFTS: 55

Oropharynx Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Oropharynx Cancer

About this section

MalaCards integrated aliases for Oropharynx Cancer:

Name: Oropharynx Cancer 12 15 17
Oropharyngeal Cancer 12 36 54 15
Malignant Neoplasm of Oropharynx 71 32
Oropharyngeal Carcinoma 12 71
Malignant Tumour of Mesopharynx 12
Malignant Oropharyngeal Tumor 12
Malignant Tumor of Oropharynx 12
Oropharyngeal Cancer, Adult 52
Cancer of the Oropharynx 52

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Oral diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:8557
KEGG 36 H01559
NCIt 49 C7398
UMLS 71 C0153382 C0153388 C0153389 more
Sources

Summaries for Oropharynx Cancer

About this section
KEGG : 36 Oropharyngeal cancer is a generic term that includes tumors arising within the anatomic confines of the posterior pharyngeal wall, soft palate, tonsillar region and posterior one-third (base) of the tongue. The vast majority of these tumors (>95%) includes squamous cell carcinomas of mucosal origin. Oropharyngeal squamous cell carcinomas (OPSCCs) are traditionally categorized as head and neck squamous cell carcinoma (HNSCC). High-risk human papillomavirus (HR-HPV) is now recognised as a causative agent in a subset of OPSCCs. HPV-driven OPSCC and tobacco- and alcohol-related OPSCC are biologically distinct entities. In the former, p53 and pRb are both inactivated at the protein level by, respectively, E6 and E7 viral oncoproteins. The majority of HPV-negative tumors, instead, harbor mutations in the TP53 gene, an increased epidermal growth factor receptor (EGFR) gene copy number and higher EGFR expression by immunohistochemistry (IHC).

MalaCards based summary : Oropharynx Cancer, also known as oropharyngeal cancer, is related to squamous cell carcinoma and anus cancer. An important gene associated with Oropharynx Cancer is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs sodium fluoride and Menthol have been mentioned in the context of this disorder. Affiliated tissues include the, tongue and lymph node, and related phenotypes are Increased viability with paclitaxel and homeostasis/metabolism

Disease Ontology : 12 A pharynx cancer that is located in the oropharynx.

Wikipedia : 74 Oropharyngeal cancer (OPC) also known as Tonsil cancer, is a disease in which abnormal cells with the... more...

Sources

Related Diseases for Oropharynx Cancer

About this section

Diseases related to Oropharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 474)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.1 TP53 ERBB2 EGFR CDKN2A CASP3
2 anus cancer 31.0 TP53 MMP8 H2AC18 EGFR CDKN2A
3 oral squamous cell carcinoma 31.0 TP53 MIR9-1 EGFR CDKN2A CASP3
4 anogenital venereal wart 30.9 TP53 H2AC18 CDKN2A
5 oral cancer 30.9 TP53 EGFR CDKN2A CASP3 ADH1C
6 nasopharyngeal carcinoma 30.9 TP53 MIR9-1 ERBB2 EGFR CDKN2A CASP3
7 squamous cell papilloma 30.8 TP53 CDKN2A
8 hypopharynx cancer 30.8 TP53 MMP8 EGFR CDKN2A ADH1C
9 cervical cancer 30.6 TP53 MIR9-1 ERBB2 EGFR CDKN2A CASP8
10 exanthem 30.6 KIT H2AC18 ERBB2 EGFR
11 penile cancer 30.5 TP53 EGFR CDKN2A
12 skin squamous cell carcinoma 30.5 TP53 EGFR CDKN2A
13 small cell carcinoma 30.4 TP53 KIT EGFR CDKN2A
14 esophagitis 30.4 TP53 EGFR CDKN2A
15 keratosis 30.4 TP53 KIT EGFR CDKN2A
16 tongue disease 30.4 TP53 MMP8 EGFR CDKN2A CASP3
17 tongue squamous cell carcinoma 30.4 TP53 MMP8 EGFR CDKN2A CASP3
18 squamous cell carcinoma, head and neck 30.4 TP53 MMP8 MIR9-1 H2AC18 ERBB2 EGFR
19 oral cavity cancer 30.4 MIR9-1 MIR193B H2AC18 ERBB2 EGFR CASP8
20 peripheral nervous system disease 30.3 TP53 SERPINA3 H2AC18 ERBB2 CASP3
21 in situ carcinoma 30.2 TP53 SERPINA3 H2AC18 ERBB2 EGFR CDKN2A
22 ovarian disease 30.2 TP53 MIR9-1 MIR193B ERBB2 EGFR CASP3
23 meningioma, familial 30.2 TP53 SERPINA3 H2AC18 ERBB2 EGFR CDKN2A
24 myelodysplastic syndrome 30.1 TP53 KIT H2AC18 ERBB2 CDKN2A CASP8
25 esophageal cancer 30.1 TP53 MIR9-1 ERBB2 EGFR CDKN2A CASP8
26 pharynx cancer 29.9 TP53 SERPINA3 NFIB MMP8 MIR9-1 MIR193B
27 suppression of tumorigenicity 12 29.8 TP53 SERPINA3 KIT H2AC18 ERBB2 EGFR
28 leukemia, acute myeloid 29.7 TP53 SERPINA3 MIR9-1 KIT H2AC18 ERBB2
29 adenoid cystic carcinoma 29.7 TP53 SERPINA3 NFIB MYBL1 KIT ERBB2
30 tonsil cancer 29.7 TP53 SERPINA3 NFIB MYBL1 MIR193B MAML2
31 ovarian cancer 29.5 TP53 SERPINA3 MIR9-1 KIT H2AC18 ERBB2
32 lung cancer susceptibility 3 29.4 TP53 SERPINA3 MIR9-1 MIR193B KIT H2AC18
33 cutaneous telangiectasia and cancer syndrome, familial 12.2
34 tendinopathy 10.7 MMP8 CASP8 CASP3
35 prostate squamous cell carcinoma 10.7 TP53 CDKN2A
36 parotid gland adenoid cystic carcinoma 10.7 ERBB2 CDKN2A
37 vulvar intraepithelial neoplasia 10.7 TP53 CDKN2A
38 endometrial squamous cell carcinoma 10.7 TP53 CDKN2A
39 malignant peritoneal mesothelioma 10.7 EGFR CDKN2A
40 cervical adenoid cystic carcinoma 10.7 NFIB KIT CDKN2A
41 lacrimal gland adenocarcinoma 10.7 TP53 NFIB ACCS
42 esophagus verrucous carcinoma 10.7 TP53 EGFR CDKN2A
43 verrucous carcinoma 10.7 TP53 EGFR CDKN2A
44 serous cystadenocarcinoma 10.7 TP53 ERBB2 CDKN2A
45 trachea adenoid cystic carcinoma 10.7 NFIB MYBL1 ACCS
46 acinar cell cystadenocarcinoma 10.6 SERPINA3 ACCS
47 bone squamous cell carcinoma 10.6 TP53 EGFR CDKN2A
48 ovarian seromucinous carcinoma 10.6 TP53 CDKN2A
49 lacrimal system cancer 10.6 NFIB MYBL1 ACCS
50 cutaneous adenocystic carcinoma 10.6 NFIB MYBL1 ACCS

Comorbidity relations with Oropharynx Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oropharynx Cancer:



Diseases related to Oropharynx Cancer
Sources

Symptoms & Phenotypes for Oropharynx Cancer

About this section

GenomeRNAi Phenotypes related to Oropharynx Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with paclitaxel GR00179-A-1 8.32 CASP3

MGI Mouse Phenotypes related to Oropharynx Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 ADH1C APC CASP3 CASP8 CDKN2A CRTC1
2 growth/size/body region MP:0005378 10.18 ADH1C APC CASP3 CASP8 CDKN2A CRTC1
3 endocrine/exocrine gland MP:0005379 10.17 APC CASP3 CASP8 CDKN2A CRTC1 EGFR
4 digestive/alimentary MP:0005381 10.06 APC CASP3 CDKN2A EGFR ERBB2 KIT
5 craniofacial MP:0005382 10.02 APC CASP3 EGFR ERBB2 KIT NFIB
6 integument MP:0010771 10.02 APC CASP3 CASP8 CDKN2A EGFR ERBB2
7 muscle MP:0005369 9.86 APC CASP3 CASP8 CDKN2A EGFR ERBB2
8 neoplasm MP:0002006 9.76 APC CASP8 CDKN2A EGFR ERBB2 KIT
9 pigmentation MP:0001186 9.43 APC CASP3 CDKN2A EGFR KIT TP53
10 respiratory system MP:0005388 9.23 CASP3 CASP8 CDKN2A EGFR ERBB2 KIT
Sources

Drugs & Therapeutics for Oropharynx Cancer

About this section

Drugs for Oropharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 sodium fluoride Approved Phase 4 7681-49-4
2
Menthol Approved Phase 4 2216-51-5 16666
3
Nicotine Approved Phase 4 54-11-5 942 89594
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
6 Anti-Infective Agents, Local Phase 4
7 Listerine Phase 4
8 Psychotropic Drugs Phase 4
9 Central Nervous System Stimulants Phase 4
10 Cholinergic Agents Phase 4
11 Nicotinic Agonists Phase 4
12 Liver Extracts Phase 4
13 Cytochrome P-450 Enzyme Inhibitors Phase 4
14 Dopamine Agents Phase 4
15 Antidepressive Agents Phase 4
16 Mitomycins Phase 4
17
Gabapentin Approved, Investigational Phase 3 60142-96-3 3446
18
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
19
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
20
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
21
Durvalumab Approved, Investigational Phase 2, Phase 3 1428935-60-7
22
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
23
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
24
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
25
Icodextrin Approved, Investigational Phase 3 337376-15-5
26 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
27 Molgramostim Investigational Phase 3 99283-10-0
28
Lobeline Investigational Phase 2, Phase 3 90-69-7
29
Tremelimumab Investigational Phase 3 745013-59-6
30 Anti-Anxiety Agents Phase 3
31 Anticonvulsants Phase 3
32 Excitatory Amino Acid Antagonists Phase 3
33 Muscarinic Agonists Phase 2, Phase 3
34 Antibodies, Monoclonal Phase 2, Phase 3
35 Immunoglobulins, Intravenous Phase 2, Phase 3
36 Immunoglobulin G Phase 2, Phase 3
37 Vaccines Phase 3
38 Pharmaceutical Solutions Phase 3
39
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
40
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
41
Indinavir Approved Phase 2 150378-17-9 5362440
42
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
43
Trioxsalen Approved Phase 2 3902-71-4 5585
44
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
45
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
46
Zinc Approved, Investigational Phase 2 7440-66-6 32051
47
Zinc oxide Approved Phase 2 1314-13-2
48
Ketorolac Approved Phase 2 66635-83-4, 74103-06-3 3826
49
nivolumab Approved Phase 2 946414-94-4
50
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907

Interventional clinical trials:

(show top 50) (show all 242)
# Name Status NCT ID Phase Drugs
1 Essential Oils With and Without Alcohol: in Vivo Antibacterial Effect Unknown status NCT03146390 Phase 4 Essential oils;Alcohol free essential oils
2 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
4 Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer Recruiting NCT03691441 Phase 4 Chemotherapy
5 Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3 cisplatin;fluorouracil
6 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
7 Effects of the Bilateral Mandibular Nerve Block (V3) in Mandibular Osteotomy: a Prospective, Randomized, Double-blind Versus Placebo Study Unknown status NCT02618993 Phase 3
8 Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma Unknown status NCT03269344 Phase 3 Gabapentin;Placebo Oral Capsule
9 Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state) Unknown status NCT00964977 Phase 3
10 A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated With Curative Radiation Therapy in Head and Neck Cancer Patients Completed NCT00008398 Phase 3
11 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
12 A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
13 A Pilot Study to Compare the Nicotine Lozenge and Tobacco-Free Snuff for Smokeless Tobacco Reduction Completed NCT01018394 Phase 2, Phase 3 nicotine lozenges;tobacco-free snuff
14 Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Completed NCT00158678 Phase 3 concomitant cisplatin
15 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
16 DART-HPV: A Phase III Evaluation of De-escalated Adjuvant Radiation Therapy for HPV-Associated Oropharynx Cancer Recruiting NCT02908477 Phase 3 Docetaxel;Cisplatin
17 A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA Recruiting NCT03811015 Phase 2, Phase 3 Cisplatin
18 Phase III Randomised Controlled Trial Comparing Alternative Regimens for Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer Recruiting NCT04116047 Phase 3 Cisplatin;Durvalumab
19 Patient Reported Outcomes in Term of Swallowing and Quality of Life After Prophylactic Versus Reactive Percutaneous Endoscopic Gastrostomy Tube Placement in Advanced Oropharyngeal Cancer Patients Treated With Definitive Chemo-radiotherapy Recruiting NCT04019548 Phase 3 Cisplatin injection
20 A Phase III Randomized Trial of Post-operative Adjuvant Nivolumab and Concomitant Chemo-radiotherapy in High-risk Patients With Resected Squamous Cell Carcinoma of Head and Neck Recruiting NCT03576417 Phase 3 Cisplatin;Nivolumab
21 A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer Recruiting NCT03952585 Phase 2, Phase 3 Cisplatin
22 A Phase III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer Recruiting NCT02215265 Phase 3 Cisplatin
23 Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin Recruiting NCT03258554 Phase 2, Phase 3
24 Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck Recruiting NCT01893307 Phase 2, Phase 3
25 Definitive Chemo-Radiotherapy With or Without Up-front Neck Dissection for Regionally Advanced Head and Neck Squamous Cell Carcinoma: A Phase III Multi-center Prospective Randomized Controlled Trial With Two Additional Observational Cohorts Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)
26 Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer Active, not recruiting NCT01302834 Phase 3 cisplatin
27 Phase III Trial Testing the Benefit of Intensity-modulated Radiotherapy With Weekly Replanifications Versus Intensity Modulated Radiotherapy With Only One Planification in Locally Advanced Oropharynx Carcinoma for Decreasing Xerostomia Active, not recruiting NCT01874587 Phase 3
28 The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer Active, not recruiting NCT01706939 Phase 3 Carboplatin
29 A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Active, not recruiting NCT02369874 Phase 3 MEDI4736;MEDI4736 + Tremelimumab;Standard of Care
30 Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia Active, not recruiting NCT01266044 Phase 3
31 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
32 Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV Not yet recruiting NCT04255849 Phase 3
33 Randomized Phase III Trial to Compare Radiation Therapy Alone With Radiation Therapy and Concomitant Anti-EGFr Antibody (C225) for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Terminated NCT00004227 Phase 3
34 A Phase III Trial of Standard Fractionation Radiation and Concurrent Single Agent Cisplatin, With and Without Docetaxel, Cisplatin, and 5-Fluorouracil Induction Chemotherapy, in Patients With Advanced Oropharyngeal Squamous Cell Cancer Terminated NCT00268372 Phase 3 cisplatin;docetaxel;5-fluorouracil
35 Adjuvant De-escalation, Extracapsular Spread, P16+, Transoral (ADEPT) Trial for Oropharynx Malignancy Terminated NCT01687413 Phase 3 Cisplatin
36 Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer Terminated NCT01066741 Phase 3 Homeodent®;1.4% Sodium Bicarbonate solution
37 Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
38 Phase II Trial: uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Unknown status NCT02960724 Phase 2
39 A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
40 A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
41 A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma) Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
42 Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx Unknown status NCT01516996 Phase 2 docetaxel and cisplatin
43 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
44 A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer Completed NCT02159703 Phase 2
45 Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer Completed NCT00006360 Phase 1, Phase 2 radioprotection
46 Neo-adjuvant Erbitux-based Chemotherapy Followed by Surgery and Radiotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01440270 Phase 2 Neo-adjuvant Erbitux-based chemotherapy
47 Pilot Study for the Diagnosis of Head and Neck Cancer: Photofrin and Visible Light Completed NCT00002964 Phase 2 porfimer sodium
48 A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma Completed NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
49 Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer Completed NCT01032928 Phase 2
50 Randomised Pilot Study of Therabite® Versus Wooden Spatula in the Amelioration of Trismus in Head and Neck Cancer Patients. (Trismus Trial) Completed NCT01733797 Phase 2

Search NIH Clinical Center for Oropharynx Cancer

Sources

Genetic Tests for Oropharynx Cancer

About this section
Sources

Anatomical Context for Oropharynx Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Oropharynx Cancer:

19
The

MalaCards organs/tissues related to Oropharynx Cancer:

40
Tongue, Lymph Node, Testes, Tonsil, T Cells, Lung, Breast
Sources

Publications for Oropharynx Cancer

About this section

Articles related to Oropharynx Cancer:

(show top 50) (show all 2885)
# Title Authors PMID Year
1
A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. 61 54
17378915 2007
2
Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. 61 54
9050916 1997
3
Photo-Induced Necrosis on Oropharyngeal Carcinoma (HEp-2) Cells Mediated by the Xanthene Erythrosine. 61
32384969 2020
4
Predictors of survival in patients undergoing oropharyngeal surgery for cancer recurrence after radiation therapy. 61
32193723 2020
5
Active HPV infection and its influence on survival in head and neck squamous-cell cancer. 61
32372145 2020
6
Microbiology of wound infection after oral cancer surgery. 61
32522395 2020
7
Analyzing oropharyngeal cancer survival outcomes: a decision tree approach. 61
32391712 2020
8
CD44 and associated markers in oral rinses and tissues from oral and oropharyngeal cancer patients. 61
32325304 2020
9
The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients. 61
32460181 2020
10
Oncological outcome in stage III and stage IV HPV negative oropharyngeal cancer with transoral robotic surgery (TORS). 61
31917088 2020
11
Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy. 61
32251949 2020
12
Positron Emission Tomography-Computed Tomography Surveillance after (Chemo)Radiotherapy in Advanced Head and Neck Squamous Cell Cancer: Beyond the PET-NECK Protocol. 61
32561027 2020
13
Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions. 61
32247987 2020
14
Comparing national practice versus standard guidelines for the use of adjuvant treatment following robotic surgery for oropharyngeal squamous cell carcinoma. 61
32476219 2020
15
Outcome prediction of head and neck squamous cell carcinoma by MRI radiomic signatures. 61
32500196 2020
16
The association of smoking and outcomes in HPV-positive oropharyngeal cancer: A systematic review. 61
32521295 2020
17
Patients undergoing primary surgery for oral and oropharyngeal cancer: how many are referred on the two-week wait pathway and by whom? 61
32538126 2020
18
A Genome-Wide Association Study Identifies Two Novel Susceptible Regions for Squamous Cell Carcinoma of the Head and Neck. 61
32276964 2020
19
Mass Spectrometric Comparison of HPV-Positive and HPV-Negative Oropharyngeal Cancer. 61
32545200 2020
20
Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer. 61
32234612 2020
21
Identification of novel methylation markers in HPV-associated oropharyngeal cancer: genome-wide discovery, tissue verification and validation testing in ctDNA. 61
32415241 2020
22
Correction: Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response. 61
32572173 2020
23
[Treatment de-intensification strategies for HPV-driven oropharyngeal cancer: A short review]. 61
32229067 2020
24
Transcervical sonography and human papillomavirus 16 E6 antibodies are sensitive for the detection of oropharyngeal cancer. 61
32129894 2020
25
Pruritic bullous skin eruption in a male patient receiving immunotherapy for oropharyngeal cancer. 61
31782147 2020
26
Prognostic value of a 15-gene hypoxia classifier in oropharyngeal cancer treated with accelerated chemoradiotherapy. 61
32080773 2020
27
Long-term outcomes of induction chemotherapy followed by chemoradiotherapy using volumetric-modulated arc therapy as an organ preservation approach in patients with stage IVA-B oropharyngeal or hypopharyngeal cancers. 61
32548612 2020
28
Computed tomography performance in predicting extranodal extension in HPV-positive oropharynx cancer. 61
31411751 2020
29
Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. 61
32502860 2020
30
Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer. 61
32576885 2020
31
Rethinking the 10-pack-year rule for favorable human papillomavirus-associated oropharynx carcinoma: A multi-institution analysis. 61
32167593 2020
32
Awareness Levels of the Link Between Oropharyngeal Cancer and HPV Infection Among Spanish Women: a Hospital-Based Cross-sectional Study. 61
32578035 2020
33
The Effect of Continuing Education on Dental Hygienists' Knowledge, Attitudes, and Practices Regarding Human Papillomavirus Related Oropharyngeal Cancer. 61
32554412 2020
34
Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking. 61
32079442 2020
35
Comparison of functional outcomes and health-related quality of life one year after treatment in patients with oral and oropharyngeal cancer treated with three different reconstruction methods. 61
32532572 2020
36
Sociodemographic correlates of head and neck cancer survival among patients with metastatic disease. 61
32542851 2020
37
Percutaneous retrograde left external carotid artery coil embolization for management of hemorrhage from a persistent proatlantal intersegmental artery type 2. 61
32490297 2020
38
Parents' receptiveness to oral health clinic-based vaccination. 61
32402756 2020
39
PET/MRI and genetic intrapatient heterogeneity in head and neck cancers. 61
32211941 2020
40
Suicide attempts in patients with head and neck cancer in Taiwan. 61
32128937 2020
41
De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. 61
32496903 2020
42
Analysis of dose using CBCT and synthetic CT during head and neck radiotherapy: A single centre feasibility study. 61
32226833 2020
43
Technical Note: A step-by-step guide to Temporally Feathered Radiation Therapy planning for head and neck cancer. 61
32383296 2020
44
An educational intervention on HPV knowledge and comfortability discussing vaccination among oral health care professionals of the American Indian and Alaskan Native population. 61
32401662 2020
45
Assessment of HPV 16, HPV 18, p16 expression in advanced stage laryngeal cancer patients and prognostic significance. 61
31899126 2020
46
De-intensification for HPV positive oropharyngeal cancer: and yet it moves!: 2019 in review. 61
32195379 2020
47
Changes in head and neck oncologic practice during the COVID-19 pandemic. 61
32357380 2020
48
Palatine Tonsilloliths and Actinomyces: A Multi-institutional Study of Adult Patients Undergoing Tonsillectomy. 61
32366151 2020
49
The Role of HPV and Non-HPV Sexually Transmitted Infections in Patients with Oropharyngeal Carcinoma: A Case Control Study. 61
32397254 2020
50
Hazard of Cervical, Oropharyngeal, and Anal Cancers in HIV-Infected and HIV-Uninfected Medicaid Beneficiaries. 61
32385117 2020
Sources

Variations for Oropharynx Cancer

About this section

Cosmic variations for Oropharynx Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM90409508 upper aerodigestive tract,oropharynx,carcinoma,squamous cell carcinoma c.3734G>A p.R1245Q 16:2081718-2081718 0
Sources

Expression for Oropharynx Cancer

About this section
Search GEO for disease gene expression data for Oropharynx Cancer.
Sources

Pathways for Oropharynx Cancer

About this section

Pathways related to Oropharynx Cancer according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 36
Show member pathways
 12.69 TP53 MAML2 KIT ERBB2 EGFR CASP8
2
Endometrial cancer 36
Show member pathways
 12.66 TP53 KIT ERBB2 EGFR CDKN2A CASP3
3
MAPK signaling pathway 36 1
12.64 TP53 KIT ERBB2 EGFR CASP8 CASP3
4
Gastric cancer 36
Show member pathways
 12.62 TP53 KIT ERBB2 EGFR CDKN2A APC
5
Pathways in cancer 36
12.48 TP53 KIT ERBB2 EGFR CDKN2A CASP8
6
Apoptosis Pathway 70
Show member pathways
 12.33 TP53 ERBB2 EGFR CASP8 CASP3
7
DNA Damage Response 1
Show member pathways
 12.31 TP53 CDKN2A CASP8 CASP3
8
Translation Non-genomic (rapid) action of Androgen Receptor 22
Show member pathways
 12.24 TP53 ERBB2 EGFR APC
9
Proteoglycans in cancer 36
12.23 TP53 ERBB2 EGFR CASP3
10
Viral carcinogenesis 36
12.22 TP53 CDKN2A CASP8 CASP3
11
Colorectal Cancer Metastasis 63
12.11 TP53 EGFR CASP3 APC
12
Integrated Breast Cancer Pathway 1
12.06 TP53 EGFR CASP8 CASP3
13
UVA-Induced MAPK Signaling 63
Show member pathways
 11.99 TP53 EGFR CASP8 CASP3
14
MAPK Pathway 70
Show member pathways
 11.95 TP53 ERBB2 EGFR CASP8
15
DNA Damage Response (only ATM dependent) 1
11.91 TP53 ERBB2 CDKN2A APC
16
Alzheimers Disease 1
11.89 TP53 MIR9-1 MIR1307 CASP8 CASP3
17
Glioblastoma Multiforme 63
11.87 TP53 EGFR CDKN2A APC
18
VEGF Pathway (Tocris) 60
Show member pathways
 11.74 KIT CASP8 CASP3
19
MicroRNAs in cancer 36
11.72 TP53 MIR9-1 MIR193B ERBB2 EGFR CDKN2A
20
Association Between Physico-Chemical Features and Toxicity Associated Pathways 1
11.64 ERBB2 EGFR APC
21
AGE/RAGE pathway 1
11.62 EGFR CASP8 CASP3
22
Bladder cancer 36 1
11.62 TP53 ERBB2 EGFR CDKN2A
23
Central carbon metabolism in cancer 36
11.58 TP53 KIT ERBB2 EGFR
24
Pathways Affected in Adenoid Cystic Carcinoma 1
11.52 TP53 NFIB MYBL1 ERBB2
25
Copper homeostasis 1
11.51 TP53 CASP3 APC
26
Photodynamic therapy-induced AP-1 survival signaling. 1
11.48 TP53 EGFR CDKN2A
27
Integrated Cancer Pathway 1
11.42 TP53 CASP8 CASP3
28
Platinum drug resistance 36
11.22 TP53 ERBB2 CDKN2A CASP8 CASP3
29
Extracellular vesicle-mediated signaling in recipient cells 1
11.19 ERBB2 EGFR APC
Sources

GO Terms for Oropharynx Cancer

About this section

Cellular components related to Oropharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 TP53 SERPINA3 NFIB MYBL1 MIR9-1 MAML2
2 death-inducing signaling complex GO:0031264 8.62 CASP8 CASP3

Biological processes related to Oropharynx Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.95 TP53 NFIB MYBL1 MAML2 EGFR CRTC1
2 positive regulation of gene expression GO:0010628 9.91 TP53 MMP8 KIT ERBB2 CDKN2A
3 negative regulation of cell proliferation GO:0008285 9.83 TP53 NFIB MIR9-1 CDKN2A APC
4 positive regulation of kinase activity GO:0033674 9.63 KIT ERBB2 EGFR
5 tongue development GO:0043586 9.54 KIT EGFR
6 positive regulation of MAP kinase activity GO:0043406 9.54 KIT ERBB2 EGFR
7 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.52 TP53 EGFR
8 somatic stem cell division GO:0048103 9.49 KIT CDKN2A
9 regulation of microtubule-based process GO:0032886 9.48 ERBB2 APC
10 negative regulation of ERBB signaling pathway GO:1901185 9.32 ERBB2 EGFR
11 response to cobalt ion GO:0032025 9.26 CASP8 CASP3
12 negative regulation of immature T cell proliferation in thymus GO:0033088 9.16 ERBB2 CDKN2A
13 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.13 CDKN2A CASP3 APC
14 response to antibiotic GO:0046677 8.8 TP53 CASP8 CASP3

Molecular functions related to Oropharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.43 TP53 ERBB2 EGFR
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.16 CDKN2A CASP3
3 cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097199 8.96 CASP8 CASP3
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 KIT ERBB2 EGFR
Sources

Sources for Oropharynx Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....